{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:22:40Z","timestamp":1772990560946,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Atopic dermatitis (AD) is a chronic skin disease marked by pruritus and barrier disruption. Though topical corticosteroids are standard, prolonged use may cause adverse effects. This updated meta\u2010analysis assesses the efficacy and safety of ruxolitinib cream, a topical JAK1\/JAK2 inhibitor, versus vehicle in AD treatment. PubMed, Embase, and Cochrane were searched up to April 2025 for RCTs evaluating ruxolitinib versus vehicle, following Cochrane and PRISMA guidelines. Primary outcomes included Investigator's Global Assessment\u2014Treatment Success (IGA\u2010TS) and 75% improvement in the Eczema Area and Severity Index (EASI75) at weeks 4 and 8; secondary outcomes included \u22654\u2010point improvement in pruritus Numeric Rating Scale (NRS) at week 8 and incidence of at least one treatment\u2010emergent adverse event (TEAE). Five RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091912) were included. Ruxolitinib significantly improved IGA\u2010TS at 4\u2009weeks (RR 4.56; 95% CI 3.01\u20136.92;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001) and 8\u2009weeks (RR 4.00; 95% CI 2.97\u20135.38;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001), and EASI75 at 4\u2009weeks (RR 3.10; 95% CI 1.79\u20135.38;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001) and 8\u2009weeks (RR 3.16; 95% CI 2.21\u20134.51;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001). Benefits were consistent across age groups and dosages. Trial sequential analysis confirmed results' robustness. Pruritus NRS improved (RR 2.39; 95% CI 1.62\u20133.53;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.001). TEAE risk was similar (RR 0.87; 95% CI 0.74\u20131.03;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.10), though adolescents\/adults had fewer events (RR 0.83; 95% CI 0.69\u20131.00;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.04); children showed no significant increase (RR 1.14; 95% CI 0.74\u20131.75;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.55). Ruxolitinib cream significantly improves IGA\u2010TS, EASI75, and pruritus, with a comparable safety profile to vehicle.\n                  <\/jats:p>","DOI":"10.1111\/pai.70281","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:35:36Z","timestamp":1768905336000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7918-0107","authenticated-orcid":false,"given":"Laura","family":"Ghanem","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences Lebanese University  Beirut Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-5166","authenticated-orcid":false,"given":"Daniela Luc\u00eda","family":"Mendoza\u2010Mill\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Dermatology Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Dermatology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1631-293X","authenticated-orcid":false,"given":"B\u00e1rbara Baptista","family":"Lopes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Faculdade de Filosofia Ci\u00eancias e Letras de Pen\u00e1polis  S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-9305","authenticated-orcid":false,"given":"Martin","family":"Cevallos\u2010Cueva","sequence":"additional","affiliation":[{"name":"School of Medicine Universidad Central del Ecuador  Quito Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2496-6119","authenticated-orcid":false,"given":"Devanie","family":"Martani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Tarumanagara  Jakarta Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8998-4519","authenticated-orcid":false,"given":"Cristina","family":"Sicorschi Gutu","sequence":"additional","affiliation":[{"name":"Medgate AG  Allschwil Switzerland"},{"name":"University Clinic for Psychiatry and Psychotherapy Paracelsus Medical University  Nuremberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4009-0525","authenticated-orcid":false,"given":"Virginia","family":"Velasco\u2010Tamariz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario 12 de Octubre, I+12 Research Institute Universidad Complutense  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-6457","authenticated-orcid":false,"given":"Peter","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Dermatology Harvard Medical School  Boston Massachusetts USA"},{"name":"Department of Dermatology Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130"},{"key":"e_1_2_12_3_1","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier W","year":"2020","journal-title":"AFP"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411380"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005\/full"},{"key":"e_1_2_12_6_1","article-title":"Topical anti\u2010inflammatory treatments for eczema: network meta\u2010analysis","volume":"8","author":"Lax SJ","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2025.46.240113"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0008"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14485"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2435657"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22014"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2480744"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"e_1_2_12_19_1","unstructured":"Study Details | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1)\u2014An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT03745638?cond=NCT03745638&rank=1(accessed 25 Apr2025)"},{"key":"e_1_2_12_20_1","unstructured":"Incyte Corporation.Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2)\u2014A Phase 3 Double\u2010Blind Randomized 8\u2010Week Vehicle\u2010Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long\u2010Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis. clinicaltrials.gov.2023https:\/\/clinicaltrials.gov\/study\/NCT03745651. (accessed 25 Apr2025)"},{"key":"e_1_2_12_21_1","unstructured":"Chapter\u00a010: Analysing data and undertaking meta\u2010analyses.https:\/\/training.cochrane.org\/handbook\/current\/chapter\u201010(accessed 13 May2025)"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2024.05.008"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1385"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.009"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.07.010"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1443704"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.041"},{"key":"e_1_2_12_31_1","unstructured":"Incyte Corporation.A Phase 3b Double\u2010Blind Multicenter Randomized Vehicle\u2010Controlled Efficacy and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis.2025clinicaltrials.govhttps:\/\/clinicaltrials.gov\/study\/NCT06238817(accessed 25 Apr2025)"},{"key":"e_1_2_12_32_1","unstructured":"Incyte Corporation.A phase 3b double\u2010blind multicenter randomized vehicle\u2010controlled efficacy and safety study of Ruxolitinib cream in children and adolescents (6 to 18\u2009years old) with moderate atopic dermatitis.2025clinicaltrialsgovhttps:\/\/clinicaltrials.gov\/study\/NCT06832618(accessed 25 Apr2025)"},{"key":"e_1_2_12_33_1","unstructured":"Chinese Clinical Trial Register (ChiCTR).The world health organization international clinical trials registered organization registered platform.https:\/\/www.chictr.org.cn\/showprojEN.html?proj=229623(accessed 25 Apr2025)"},{"key":"e_1_2_12_34_1","unstructured":"Search for clinical trials\u2014EMA.https:\/\/euclinicaltrials.eu\/search\u2010for\u2010clinical\u2010trials\/?lang=en&EUCT=2023\u2010505433\u201027\u201000(accessed 25 Apr2025)"},{"key":"e_1_2_12_35_1","unstructured":"Taro Pharmaceuticals USA.A Multi\u2010Center Double\u2010Blind Randomized Placebo\u2010Controlled Parallel\u2010Group Study Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A Inc.) to OPZELURA (Ruxolitinib) Cream and Both Active Treatments to a Placebo Control in the Treatment of Mild\u2010to\u2010Moderate Atopic Dermatitis.2024clinicaltrials.govhttps:\/\/clinicaltrials.gov\/study\/NCT06673654(accessed 25 Apr2025)"},{"key":"e_1_2_12_36_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215309s001lbl.pdf(accessed 25 Apr2025)."},{"key":"e_1_2_12_37_1","unstructured":"Opzelura (ruxolitinib) FDA Approval History.Drugs.com.https:\/\/www.drugs.com\/history\/opzelura.html(accessed 25 Apr2025)"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00610-x"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18429"},{"key":"e_1_2_12_41_1","unstructured":"British Association of Dermatologists.https:\/\/www.bad.org.uk\/pils\/atopic\u2010eczema\/(accessed 25 Apr2025)."},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"e_1_2_12_43_1","article-title":"Topical anti\u2010inflammatory treatments for eczema: network meta\u2010analysis","volume":"2024","author":"Lax SJ","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-02971-6"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01569-x"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.70281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pai.70281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.70281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:25:16Z","timestamp":1772972716000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.70281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/pai.70281"],"URL":"https:\/\/doi.org\/10.1111\/pai.70281","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/PAI.70281\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.70281\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.70281\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.70281\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/PAI.70281\/v1\/review2","asserted-by":"object"}]},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70281"}}